CKMM
- Known as:
- CKMM
- Catalog number:
- AS101318
- Product Quantity:
- 1 mg
- Category:
- -
- Supplier:
- Agris
- Gene target:
- CKMM
Related genes to: CKMM
- Gene:
- CKM NIH gene
- Name:
- creatine kinase, M-type
- Previous symbol:
- CKMM
- Synonyms:
- -
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-02-10
Related products to: CKMM
Related articles to: CKMM
- Cardiovascular-kidney-metabolic (CKM) syndrome is increasingly recognized as a distinct disorder with important implications for health outcomes, but its heterogeneity of presentation and genetic underpinning remains poorly understood. We aimed to identify potential CKM subtypes and their genetic basis by analyzing biomarkers and health outcomes in a large biobank. - Source: PubMed
Publication date: 2026/01/31
Donker Hylke CBisht VartikaDwivedi Om PrakashMueller StefanieNeijzen DorienDing ZhihaoLunter Gerton - Individuals in the early stages (Stages 0-3) of Cardiovascular-Kidney-Metabolic (CKM) syndrome represent a critical window for cardiovascular disease (CVD) prevention. Adverse Childhood Experiences (ACEs), significant psychosocial risk factors, may accelerate CVD progression in this population through underlying biological pathways, but these mediating mechanisms remain unvalidated in large longitudinal cohorts. The research aimed to determine the independent impact of ACEs on CVD incidence in early-stage CKM individuals and systematically study the core mediating role of depressive symptoms, including its variation across population subgroups. - Source: PubMed
Publication date: 2026/01/25
Chen ZengyuZhao WeiChen ZepingTian KaixinQin YaluYu YaXie Rui - The Frailty Index (FI) is a well-established predictor of accelerated biological aging and a reliable tool for estimating all-cause and cardiovascular disease (CVD) mortality in older adults in the United States. However, its predictive value remains unclear in other U.S. population subgroups. This study aimed to examine the association between FI levels and both all-cause and CVD mortality among patients diagnosed with Cardiovascular-Kidney-Metabolic Syndrome (CKM syndrome). - Source: PubMed
Publication date: 2026/01/29
Wang XinHai XinruiMa AliLiang XiaolanCheng HuaWu PengHao YuChen DapengYan Ning - - Source: PubMed
Publication date: 2026/01/30
Anderer Samantha - Cardiovascular-kidney-metabolic (CKM) syndrome was recently identified as a cardiometabolic disorder that incorporates chronic kidney disease with the metabolic syndrome (MetS). REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was an international, double-blind, placebo-controlled trial that randomized hypertriglyceridemic (TG, 150-499 mg/dL) statin-treated patients with established cardiovascular disease (CVD) or diabetes and multiple CVD risk factors to icosapent ethyl (IPE) or placebo (4 grams/day). It is unknown if renal insufficiency added to MetS confers incremental CVD risk in secondary prevention patients without diabetes and if IPE lowers that risk. - Source: PubMed
Publication date: 2025/12/19
Miller MichaelBhatt Deepak LBrinton Eliot AJacobson Terry ASteg Ph GabrielKetchum Steven BPineda Armando LiraTardif Jean-ClaudeBallantyne Christie M